Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
Nasal mucosal immunization is very attractive for vaccination to prevent various bacterial and viral infectious diseases because of induction of systemic and mucosal immune responses. The aim of the present study was to investigate the possibility of changing the immunization procedure of diphtheria toxoid (DT) from intramuscular or subcutaneous injection to intranasal administration. Intranasal immunization with aluminium-non-adsorbed diphtheria toxoid (nDT) together with recombinant cholera toxin B subunit (rCTB, 10 microg) induced, at a concentration of 5 Lf, high levels of serum DT-specific IgG antibody responses and high or moderate levels of the specific IgA antibody responses in all mice and only a slight level of the specific IgE antibody responses in some mice. Furthermore, sufficiently high diphtheria antitoxin titres more than 0.1 international units (IU) ml(-1) were obtained from mice which showed high levels of serum DT-specific IgG antibody responses. Under the same experimental conditions, induction of significant levels of mucosal DT-specific IgA antibody responses occurred in the nasal cavity, the lung, the saliva and vaginal secretions and the small and large intestines of all mice, although there were different titres between individual mice. Similar results were also obtained with rCTB-specific serum IgG and IgA and mucosal IgA antibody responses; serum rCTB-specific IgE antibody titres were not detected. These results show that intranasal administration of nDT with rCTB must be a very useful means for vaccination against diphtheria.
Isaka
M
M
Department of Microbiology, Nagoya City University Medical School, Mizuho-ku, Nagoya, Japan.
Yasuda
Y
Y
Kozuka
S
S
Taniguchi
T
T
Matano
K
K
Maeyama
J
J
Komiya
T
T
Ohkuma
K
K
Goto
N
N
Tochikubo
K
K
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000737:chemistry; D000281:Administration, Intranasal; D000327:Adsorption; D000535:Aluminum / Q000008:administration & dosage / Q000737:chemistry; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000097:blood; D000918:Antibody Specificity; D002772:Cholera Toxin / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D004165:Diphtheria / Q000276:immunology / Q000517:prevention & control; D004166:Diphtheria Antitoxin / Q000097:blood / Q000276:immunology; D004168:Diphtheria Toxoid / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D018928:Immunity, Mucosal / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009297:Nasal Mucosa / Q000276:immunology*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000737:chemistry
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D004166:Diphtheria Antitoxin; D004168:Diphtheria Toxoid; D011994:Recombinant Proteins; D002772:Cholera Toxin; D000535:Aluminum